/
AMRN
$15.92+$0.01 (+0.06%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$333.6M
21M shares
52-week range
$12.96 – $20.90
37% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-71.68
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $229.2M | $429.8M | $614.1M | $583.2M | $369.2M | $306.9M | $228.6M | $213.6M |
| Cost of revenue | $54.5M | $96.0M | $131.4M | $121.3M | $126.7M | $141.4M | $147.2M | $92.8M |
| Gross profit | $174.7M | $333.7M | $482.6M | $461.9M | $242.5M | $165.5M | $81.4M | $120.9M |
| Gross margin | 76.2% | 77.7% | 78.6% | 79.2% | 65.7% | 53.9% | 35.6% | 56.6% |
| R&D | $55.9M | $34.4M | $39.0M | $29.3M | $30.4M | $22.2M | $20.9M | $19.8M |
| Operating income | −$108.2M | −$24.3M | −$19.7M | $10.5M | −$105.9M | −$56.6M | −$91.8M | −$13.9M |
| EBITDA | −$106.6M | −$15.0M | −$12.7M | $14.3M | −$100.7M | −$50.7M | −$74.2M | −$33.0M |
| Net income | −$116.4M | −$22.6M | −$18.0M | $7.7M | −$105.8M | −$59.1M | −$82.2M | −$38.8M |
| Net margin | -50.8% | -5.3% | -2.9% | 1.3% | -28.7% | -19.3% | -35.9% | -18.2% |
| EPS (diluted) | -7.80 | -1.32 | -1.00 | 0.38 | -5.20 | -3.00 | -4.00 | -1.80 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $182M | $-0.04 | $-0.04–$-0.03 | 1 |
| 2027 | $193M | $0.06 | $0.05–$0.06 | 1 |
| 2028 | $188M | $0.07 | $-0.04–$0.17 | 2 |
| 2029 | $234M | $0.19 | $0.18–$0.20 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Amarin Corp Plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
www.amarincorp.com- Employees
- 80
- IPO / List date
- Apr 1, 1993
- HQ
- DUBLIN 2
Held by traders on TradeandTell
No one on the platform currently holds AMRN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 19,256 | $278.4K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-04-11 | 1-for-20reverse |
| 2008-01-18 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded AMRN yet.
